Means and methods for healing chronic wounds
Inhibiting the Slc7a11 transporter in dendritic cells enhances apoptotic cell uptake, addressing the failure of efferocytosis in chronic wounds, thereby accelerating healing and reducing inflammation, especially in diabetic wounds.
Patent Information
- Application Number
- JP2024525682
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-10-26
- Publication Date
- 2024-11-13
AI Technical Summary
Chronic wounds, such as those associated with diabetes, aging, or vascular disease, fail to heal properly due to unresolved inflammation caused by the failure of efferocytosis, a process in which apoptotic cells are cleared by phagocytes, leading to significant morbidity and medical costs.
Inhibition of the Slc7a11 transporter in dendritic cells using pharmacological inhibitors, siRNA knockdown, or genetic deletion enhances apoptotic cell uptake, promoting wound healing by accelerating efferocytosis and reducing the apoptotic cell burden.
Accelerated wound healing is achieved by improving efferocytosis, reducing chronic inflammation, and enhancing the secretion of beneficial factors like GDF15, particularly in diabetic conditions, leading to faster wound closure and improved tissue regeneration.
Smart Images

Figure 2024542030000007 
Figure 2024542030000008 
Figure 2024542030000009
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to the field of tissue regeneration, particularly wounds, more particularly skin lesions such as chronic wounds.The present invention provides wound healing compositions.Specifically, the present invention provides molecules that target Slc7a11 transporter for use in treating chronic wound healing, such as diabetic wound healing. [Background technology]
[0002] Introduction to the Invention Billions of cells in the body are turned over by apoptosis every day. These dead cells are then destroyed by a process called "efferocytosis." 1 From a physiological standpoint, failure of efferocytosis is associated with unresolved inflammation resulting in a chronic inflammatory state. 2、3、4、5、6 Dendritic cells are a heterogeneous group of phagocytes present in almost all tissues. They display a battery of phagocytosis and pathogen recognition receptors and help maintain tissue homeostasis through regulation of innate and adaptive immunity. 7 The uptake of apoptotic cells by dendritic cells has long been recognized, but this has been studied primarily in the context of antigen presentation and the generation of adaptive immunity. 8、9、10、11、12 Compared with macrophages, less is known about the molecular regulation of efferocytosis in dendritic cells and the contribution of dendritic cell efferocytosis to limiting inflammation.
[0003] As the largest organ of the body, our skin acts as a barrier to protect internal tissues from extremes of temperature, water loss, ultraviolet light, microbial and chemical aggressions, and injury. Tissue repair after skin injury involves the clearance of apoptotic cells by phagocytes at the wound site, which in turn aids in the resolution of inflammation and restoration of the barrier. 13、14Chronic non-healing wounds, such as those associated with diabetes, aging, or vascular disease, severely affect quality of life and pose a significant risk of infection. 15 Homeostasis in healthy skin is maintained by immune cells, including dendritic cells, macrophages, and T cells that proliferate in the tissue. Langerhans cells (LCs), which reside in the epidermis, along with dendritic cells in the dermis, are in a state of surveillance to capture dead cells or pathogens during homeostasis and present them to effector T cells. 16、17 After skin injury, resident or recruited macrophages 18、19 and neutrophils 20 Dendritic cells are positively and negatively associated with wound healing dynamics; however, knowledge of the contribution of dendritic cells to wound repair is limited.
[0004] A chronic wound is one that fails to progress through a normal, orderly, and timely sequence of repair or where the repair process fails to restore anatomical and functional integrity after three months. Approximately 5 million patients in the United States suffer from chronic wounds. With the increase in longevity, obesity, and diabetes, chronic wound problems are on the rise, resulting in significant morbidity, time lost from work, and huge medical costs. According to the American Diabetes Association, 25% of people with diabetes will suffer from wound problems in their lifetime, and approximately 82,000 amputations for non-traumatic wounds were performed in people with diabetes in 2002. The Agency for Health Care Policy and Research reports that wound care for pressure ulcers uses $200 billion annually for hospitalizations, durable medical supplies, nursing home care, physicians, and transportation. Surgical treatment of diabetic wounds remains difficult and often inadequate, leading to high morbidity for these patients. Some chronic wounds can take decades to heal, thus contributing to secondary conditions such as depression. The 5-year mortality rate after diabetic ulcer development is approximately 40%. Despite recent advances in the understanding of wound healing, the molecular mechanisms underlying impaired wound healing are not fully understood, and currently available methods also show limited efficacy (Perez-Favila A. et al (2019) Medicina (Kaunas) 55:714). Summary of the Invention
[0005] SUMMARY OF THE PRESENT APPLICATION In this study, while seeking to understand how the genetic program of dendritic cells is modified when they phagocytose apoptotic cells, we serendipitously discovered a role for the plasma membrane protein Slc7a11 as a novel brake on dendritic cell-mediated efferocytosis and revealed its relevance to cutaneous wound healing. We show that the use of pharmacological inhibitors of Slc7a11, siRNA knockdown of Slc7a11, or genetic deletion of Slc7a11 to enhance apoptotic cell uptake by dendritic cells leads to increased wound closure in mammals.
[0006] In one aspect, the invention provides a combination comprising an inhibitor of Slc7a11 and an apoptotic cell. In yet another aspect, the present invention provides a combination comprising an inhibitor of Slc7a11 and an apoptotic cell for use as a medicament.
[0007] In yet another aspect, the present invention provides a composition comprising an inhibitor of Slc7a11 and an apoptotic cell for use in treating wound healing. In another aspect, the present invention provides an inhibitor of Slc7a11 for use in treating chronic wound healing in a mammal.
[0008] In another aspect, the present invention provides an inhibitor for use in treating chronic wound healing, wherein the inhibitor is selected from a small compound that binds to Slc7a11, an antibody conjugated to Slc7a11, a gapmer that binds to Slc7a11 mRNA, an shRNA that binds to Slc7a11 mRNA, a synthetic siRNA that binds to Slc7a11 mRNA, an antisense oligonucleotide that binds to slc7a11 mRNA selected from locked nucleic acid (LNA), peptide nucleic acid (PNA), or morpholino, a CRISPR that targets the Slc7a11 gene, a TALEN, or a zinc finger nuclease.
[0009] In certain aspects, the chronic wound is diabetic wound healing, arterial or venous wound healing, or pressure wound. In another aspect, the present invention provides a composition comprising an inhibitor of Slc7a11 and GDF-15 as defined hereinbefore for use as a medicament. In another aspect, the present invention provides a composition comprising an inhibitor of Slc7a11 and GDF-15 as defined hereinbefore for use in treating chronic wound healing.
[0010] In another aspect, the present invention provides a pharmaceutical composition comprising an inhibitor as defined hereinbefore for use in treating a chronic wound. In another aspect, the present invention provides a pharmaceutical composition comprising an inhibitor as defined hereinbefore for use in treating diabetic wound healing, arterial or venous wound healing, or chronic wound healing such as pressure wounds. [Brief description of the drawings]
[0011] Figure legend [Figure 1a-1] Figure 1: Slc7a11 acts as a subversive for dendritic cell phagocytosis of apoptotic cells. a, Schematic of phagocytosis assay with bone-marrow derived dendritic cells (BMDCs) fed with apoptotic human Jurkat cells, live cells, or plain beads (2.0 μm) (left). RNAseq was performed on sorted phagocytic BMDCs after 4 h of co-culture with targets. Histograms illustrate yellow-green (beads) and CypHer5E (cells) fluorescence in efferocytic DCs. [Figure 1a-2] The histograms illustrate yellow-green (beads) and CypHer5E (cells) fluorescence in efferocytic DCs. [Figure 1b]b, c, Genes associated with transporter activity differentially regulated after efferocytosis in dendritic cells were categorized by functionality (b) and grouped by protein family (c). Data are from four independent experimental replicates per condition.
[0012] [Figure 1c] b, c, Genes associated with transporter activity differentially regulated after efferocytosis in dendritic cells were categorized by functionality (b) and grouped by protein family (c). Data are from four independent experimental replicates per condition. [Figure 1d] d, SLC7 family gene expression was measured by qRT-PCR after phagocytosis of plain beads versus apoptotic cell uptake as in a. For clarity, Slc7a5 and Slc7a11 are highlighted in blue. Data represent three biological replicates per condition, ****P = 0.0001, two-way analysis of variance (ANOVA) with Sidak's multiple comparison test. ND, not detected.
[0013] [Figure 1e-g] e, Slc7a11 siRNA targeting increases efferocytosis of pHrodo Green-stained apoptotic cells as illustrated by live cell imaging analysis by Incucyte. f, Treatment with erastin, a pharmacological inhibitor of Slc7a11, promotes apoptotic cell uptake by dendritic cells as shown over time. g, Schematic of Slc7a11 WT and Slc7a11 KO mice and phagocytes isolated from bone marrow or spleen. [Figure 1h] h, Kinetics of efferocytosis by Slc7a11 WT and Slc7a11 KO BMDCs treated with erastin or vehicle. All live cell imaging data are expressed as mean ± SEM, n = 4–8, ****p < 0.00001; one-way ANOVA with Tukey's multiple comparison test.
[0014] [Figure 1i] i, The percentage of phagocytosis of TAMRA- or CypHer5E-labeled apoptotic Jurkat cells was compared between control and Slc7a11-null BMDCs (left panel). The percentage of phagocytosis of CypHer5E-labeled apoptotic Jurkat cells was compared between control and Slc7a11-null cDCs previously isolated from the spleens of mice with the respective genotypes. Dendritic cells were incubated with apoptotic targets for 4 h at a phagocyte:target ratio of 1:5. Data from n = 3–5 biological replicates, *p < 0.05; **p < 0.01; one-way ANOVA with Dunnett's multiple comparison test. All live-cell imaging data (e, f, h) are expressed as mean ± SEM, n = 4–8, ****p < 0.00001; one-way ANOVA with Tukey's multiple comparison test. ABC, ATP-binding cassette transporter; GPCR, G protein-coupled receptor.
[0015] [Figure 2a-c]Figure 2: Accelerated skin wound healing in the context of Slc7a11 blockade. a, Hexagonal tri-wise diagram (left) to visualize the relative expression levels of differentially expressed (DE) SLCs between dendritic cells derived from lung, spleen, and skin. Differentially expressed (DE) SLC genes (orange) and not (grey) are shown. Proximity represents upregulation in multiple populations, and distance from the origin represents the strength of this upregulation. Genes expressed 32-fold or more are plotted on the outer grid lines. Rose plot (right) depicting the 45 DE Slc genes (hence all orange dots) grouped into bins and the DC subtype in which they are most expressed. b, Dermal phagocytes enriched from ears of Slc7a11-deficient and control littermates were incubated with apoptotic Jurkat cells, and phagocytosis was assessed in each cell type. (n=5 per group; *p<0.05, unpaired t-test). c, d, Localization of CD11c+ phagocytes (red) and Slc7a11 (green) in skin sections from wounded (d2 post-wounding) skin (c). Dotted lines represent insets. Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; blue). Scale bar, 10 μm. CD11c+ phagocytes (red) capturing cleaved caspase-3 positive (green) corpses (d). Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; blue). Scale bar, 50 μm.
[0016] [Figure 2d] c, d, Localization of CD11c+ phagocytes (red) and Slc7a11 (green) in skin sections from wounded (d2 post-wounding) skin (c). Dotted line represents inset. Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; blue). Scale bar, 10 μm. CD11c+ phagocytes (red) capturing cleaved caspase-3 positive (green) corpses (d). Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; blue). Scale bar, 50 μm. [Figure 2e-f]e, Annotated UMAP clustering of total live skin cells isolated from non-lesional (NL) and lesional (L) skin highlighting the expression of Slc7a11 (see Methods). The right panel depicts a tSNE plot of cells clustered in lesional skin after scRNAseq analysis. f, mRNA from total skin lysates of unwounded and wounded mice analyzed by RT-qPCR for the indicated genes (n=3-4 per condition; *p<0.05; ****p<0.0001, unpaired t-test).
[0017] [Figure 2g] g, Wound healing kinetics in wild-type mice treated with an elastin or vehicle regimen consisting of a single administration of apoptotic cells (Ap.cells) to the wound site on day 0 together with elastin or DMSO vehicle administered on days 0–2. Data represent one of four independent experiments with n = 8 mice per group after full-thickness wounding with an 8 mm punch biopsy (*p < 0.05; ***p < 0.001 between groups; two-way ANOVA with multiple comparisons). [Figure 2h-i] h, i, H&E stained skin sections of wounds from mice on elastin or vehicle regimen at different days after wounding. Scale bar: 100 µm. (h, i) Quantification of apoptotic cleaved caspase-3+ cells (n = 6–7 mice per condition; *p < 0.5 by unpaired t test). [Figure 2j-k] j, Wound healing kinetics comparing the efficacy of elastin regimens at different stages of wound repair (n=10 mice per group); ****p<0.0001; two-way ANOVA with multiple comparisons. k, Wound healing kinetics comparing Slc7a11 WT and Slc7a11 KO mice after full thickness wounding. Mice received a single dose of apoptotic cells at the time of wounding (n=6 per group, *p<0.05 between groups on the indicated days after wounding; two-way ANOVA with multiple comparisons).
[0018] [Figure 3a-b]Figure 3: Glycolysis and glycogen stores fuel enhanced efferocytosis. a, Schematic of RNA-seq analysis of Slc7a11-deficient dendritic cells phagocytosing apoptotic cells. Slc7a11-deficient or control BMDCs were cultured with TAMRA-labeled apoptotic Jurkat cells for 4 h. Phagocytes were collected and TAMRA+ cells (i.e., engulfers) were sorted directly into lysis buffer for RNA-seq analysis. Contour plot images are representative of four independent experiments. b, Pathway analysis of differentially expressed genes regulated in Slc7a11 KO engulfers compared to WT engulfers. Several genes (depicted in bold and highlighted in grey boxes) falling into gluconeogenesis and diabetes / obesity transcriptional programs were selected for further analysis. Data are from three to four independent experimental replicates.
[0019] [Figure 3c-d] c, Measurement of glycogen in lysates of dendritic cell populations from WT mice treated with erastin or from Slc7a11 KO mice. (*p<0.05; **p<0.01; unpaired t-test or via one-way ANOVA with Tukey's multiple comparison test). Results are expressed as fold change (FC) from WT or DMSO-treated dendritic cells. ns, not significant. d, Schematic of glycogen metabolic pathway (left), indicating glycogen degradation steps inhibited by CP-91149. Effects on glycogen levels in BMDCs treated with erastin or CP-91149 or both (middle panel). Kinetics of efferocytosis after erastin or erastin+CP-91149 treatment (right). DMSO was used as vehicle control and CytoD was used as negative control for efferocytosis. All live-cell imaging data are expressed as mean ± SEM, n = 3–5 (*p < 0.05; ****p < 0.00001. One-way ANOVA with Tukey's multiple comparison test).
[0020] [Figure 3e]e, Increased aerobic glycolysis in dendritic cells during apoptotic cell clearance and Slc7a11 inhibition. Glycolysis and OXPHOS were measured via extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in resting dendritic cells or during efferocytosis using Seahorse XF. Data represent mean ± SEM of n = 4; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by unpaired t test or two-way ANOVA with Tukey's multiple comparison test). [Figure 3f] f, Schematic of the aerobic glycolysis pathway with each inhibitor, and the kinetics of efferocytosis by BMDCs treated with the indicated glycolysis inhibitors. All live-cell imaging data are expressed as mean ± SEM, n = 4–5 (**p < 0.01; ****p < 0.00001. One-way ANOVA with Tukey's multiple comparison test).
[0021] [Figure 4a-c] Figure 4: Slc7a11 inhibition and GDF15 promote diabetic skin wound healing. a, Delayed cutaneous wound healing in diabetic (db / db) mice versus normoglycemic (B6) mice. (n=11 per group, ****p<0.0001 between groups at each day after wounding; two-way ANOVA with multiple comparisons). b, Total skin lysates were prepared from unwounded and wounded (4 days after wounding) in WT, db / db, and GDF15 KO mice, and mRNA was isolated followed by RT-qPCR analysis of Slc7a11 (n=4–6 per group; data presented as fold change relative to Slc7a11 expression in unwounded skin per group). c, Elastin alone improves cutaneous wound healing in diabetic mice. Wound healing kinetics in db / db mice treated with water-soluble imidazole ketone elastin (elastin) or DMSO for vehicle control ( n = 7–8 mice per group, * p < 0.05 between groups on each day after wounding; two-way ANOVA with multiple comparisons).
[0022] [Fig. 4d-f]d, Elastin regimen accelerates skin wound healing in diabetic mice. Wound healing kinetics in db / db mice treated with the elastin regimen (or vehicle). Data shown represent one of three independent experiments with n=7–8 mice per group following full-thickness wounding with 8 mm punch biopsies (*p<0.05 or **p<0.01 between groups on the indicated days after wounding; two-way ANOVA with multiple comparisons). (Ap.Cells refers to apoptotic cells). e, Elastin-mediated Slc7a11 inhibition enhances efferocytosis in dendritic cells from diabetic mice. Efferocytosis data are expressed as mean ± SEM, n=4–7, ***p<0.001 ****p<0.0001. One-way ANOVA with Tukey's multiple comparisons test. f, Quantification of the number of apoptotic cells in wound biopsies staining positive for cleaved caspase-3 in wound skin of db / db mice treated with erastin or vehicle (n = 4 mice per condition; (*p < 0.5 by unpaired t test).
[0023] [Figure 4g-h] g, Wound healing kinetics in wild-type mice (n=10 per group) treated with supernatants from efferocytic Slc7a11 KO and control dendritic cells after full-thickness wounding (*p<0.05 between groups on the indicated days after wounding; two-way ANOVA with multiple comparisons). All wound sizes are expressed as percentages of initial wound size. Data represent mean ± SEM. h, (left) Heatmap showing regulation of genes belonging to the TGF superfamily. Data are from three independent experimental replicates per condition and are scaled by columns resulting in z-scores centered at 0. (right) GDF-15 secretion was assessed by ELISA in supernatants of WT and Slc7a11-KO efferocytic dendritic cells 12 h after incubation with apoptotic targets or apoptotic targets alone. n=4, *p<0.05 ***p<0.001. One-way ANOVA with Tukey's multiple comparison test.
[0024] [Figure 4i-k]i, GDF15 levels in unwounded and wounded skin lysates (2 and 8 days after wounding) by ELISA. j, Wound healing kinetics comparing GDF15 KO mice with littermate control mice after full thickness wounding (n=16 per group, **p<0.01 between the two groups by unpaired t-test). k, Topical administration of recombinant GDF15 to wounded skin of diabetic mice boosts healing (n=10-11 per group, *p<0.05 between groups on the indicated days after wounding; two-way ANOVA with multiple comparisons).
[0025] [Figure 5a-b] Figure 5: Analysis of amino acid transporters during dendritic cell efferocytosis. a, The SLC program was regulated in dendritic cells during efferocytosis of apoptotic cells compared to sterile phagocytosis. RNAseq was performed on apoptotic human Jurkat cells or primary BMDCs after phagocytosis of beads. Heatmap illustrates that SLC is up- and downregulated during dendritic cell efferocytosis. b, Uptake of CypHer5E-labeled apoptotic Jurkat cells by dendritic cells silenced for Slc7a1 expression (BMDCs).
[0026] [Figure 5c-f]c, Slc7a5 siRNA targeting in dendritic cells does not significantly affect apoptotic cell uptake as assessed by Incucyte live cell imaging. Data are expressed as mean ± SD, n=4. d, Efferocytosis of TAMRA-labeled apoptotic Jurkat cells by dendritic cells treated with different concentrations of the Slc7a5 inhibitor JPH-203. (n=2 per condition). e, Kinetics of efferocytosis by BMDCs treated with 3 μM JPH-203. Live cell imaging data are expressed as mean ± SEM, n=3. f, Measurement of degradation of TAMRA (pH-insensitive) and Cell Trace Violet (pH-sensitive) co-labeled apoptotic targets following efferocytosis by Slc7a11 KO and WT dendritic cells. Dendritic cells were incubated with apoptotic targets at a phagocyte:target ratio of 1:5 for 4 h.
[0027] [Figure 5g-h] g, Kinetics of efferocytosis by Slc7a11 WT and Slc7a11 KO bone marrow-derived macrophages with or without erastin treatment. All live cell image data are expressed as mean ± SEM, n = 4, ns: not significant. One-way ANOVA with Tukey's multiple comparison test. h, Efferocytosis by peritoneal macrophages after erastin-mediated Slc7a11 inhibition. (n = 3 per condition; ns: not significant, with unpaired t test).
[0028] [Figure 6a-d]Figure 6: Ferroptosis inducers and DC efferocytosis. a, Phagocytosis of E. coli bioparticles by dendritic cells measured at different time points with or without erastin treatment. b, Ferroptosis inducer ML-162 does not enhance efferocytosis by dendritic cells. Live cell imaging data are expressed as mean ± SEM, n = 4–6, ***p < 0.001; ****p < 0.0001. One-way ANOVA with Tukey's multiple comparison test). c, Measurement of glutathione levels in erastin-treated dendritic cells. d, Assessment of erastin drug cytotoxicity in dendritic cells by measuring Sytox Green fluorescence. [Figure 6e-f] e, Measurement of lipid peroxidation and ROS in dendritic cells treated with ferroptosis inducers. f, Kinetics of efferocytosis by dendritic cells treated with glutamate. Live cell imaging data are expressed as mean ± SEM, n = 4–6, **p < 0.01. One-way ANOVA with Tukey's multiple comparison test).
[0029] [Figure 7a] Figure 7: Analysis of skin DCs and wound healing. a, Gating strategy for enriched phagocytes after ear digestion and lymphocyte depletion. [Figure 7b-e] b, Immunofluorescence images of skin sections from unwounded PDGFR-GFP mice depicting Slc7a11 positive (red) cells. Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole; blue). Scale bar, 50 μm. c, Annotation of innate immune cell populations occurring in lesional skin. d, Frequency of Slc7a11 expression in innate immune cells in lesional and non-lesional skin. e, Representative images of wounds from mice treated with elastin or vehicle at 10 days post-wounding. [Fig. 7f-g]f, Wound healing kinetics after full thickness wounding of WT (C57B / 6) mice compared with 8 mm punch biopsies and a single topical application of apoptotic target on the day of wounding (n = 8 per group), or elastin alone on days 0-2 (n = 8 per group). g, Comparison of wound closure on day 2 after wounding in WT mice treated with RSL3 regimen versus elastin regimen. All mice received a single topical application of apoptotic target on the day of wounding (n = 7-9 per group, *p < 0.05; **p < 0.01, one-way ANOVA with Tukey's multiple comparison test).
[0030] [Figure 8a-1] Figure 8: Gene expression patterns in Slc7a11 KO efferocytic dendritic cells. a, Heatmap comparing efferocytic Slc7a11 KO to WT dendritic cells showing up- and down-regulation of genes related to metabolic and mitochondrial function, protein synthesis, ER homeostasis, transcriptional regulation, signal transduction, wound healing, cell cycle, migration, and other transporters. Data are from 3-4 independent experimental replicates. Gdf15 falls under the transcriptional program of metabolic function and regeneration and is highlighted in red. [Figure 8a-2] a. Heatmap comparing efferocytic Slc7a11 KO and WT dendritic cells showing up- and down-regulation of genes related to metabolism and mitochondrial function, protein synthesis, ER homeostasis, transcriptional regulation, signal transduction, wound healing, cell cycle, migration, and other transporters. Data are from 3-4 independent experimental replicates. Gdf15 falls under the transcriptional program of metabolic function and regeneration and is highlighted in red.
[0031] [Figure 9a-b]Figure 9: Metabolic inhibitors and DC efferocytosis a, Reserve capacity was measured in dendritic cells after vehicle or erastin treatment or during efferocytosis (by Seahorse XF) using oxygen consumption rate (OCR). n=4; *p<0.05; **p<0.01; ***p<0.001, data from one-way ANOVA with Tukey's multiple comparison test). b, Evaluation of cytotoxicity of drugs tested on dendritic cells by measuring Sytox Green fluorescence.
[0032] [Figure 9c] c, Kinetics of efferocytosis by WT BMDCs treated with the indicated inhibitors DON or UK5099. All live cell imaging data are expressed as mean ± SEM of n = 3 (*p < 0.05; ns: not significant by one-way ANOVA with Tukey's multiple comparison test). [Figure 10] Figure 10: GDF15 deficiency does not impair DC efferocytosis. a, Kinetics of efferocytosis by GDF15 KO and WT BMDCs with and without erastin treatment. All live-cell imaging data are expressed as mean ± SEM, n = 6–9, one-way ANOVA with Tukey's multiple comparison test). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] Detailed Description of the Invention The present invention will be described with respect to certain embodiments and with reference to certain drawings, but the present invention is not limited thereto, but only by the claims. Any reference signs in the claims should not be construed as limiting the scope. Of course, it should be understood that not necessarily all aspects or advantages can be achieved according to any particular embodiment of the present invention. Thus, for example, a person skilled in the art will recognize that the present invention can be embodied or made to achieve or optimize one advantage or advantages taught herein without necessarily achieving other aspects or advantages that may be taught or suggested herein. The present invention, together with its features and advantages, can be best understood by reference to the following detailed description when read in conjunction with the accompanying drawings. The aspects and advantages of the present invention will become apparent and elucidated with reference to the embodiment(s) described herein below. Reference throughout this specification to "one embodiment" or "embodiment" means that a particular feature, structure, or characteristic described with respect to the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may be. Similarly, in describing exemplary embodiments of the invention, it will be understood that various features of the invention may be grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in understanding one or more of the various inventive aspects. However, this method of disclosure should not be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim.
[0034] When an indefinite or definite article (e.g., "a" or "a", "the") is used when referring to a singular noun, this includes a plural of that noun unless something else is specifically stated. When the term "comprising" is used in the specification and claims, it does not exclude other elements or steps. Furthermore, the terms first, second, third, and other similar terms in the specification and claims are used to distinguish between similar elements and are not necessarily intended to describe a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operating in sequences other than those described or illustrated herein. The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning to those skilled in the art of the invention. Practitioners are particularly advised to consult Sambrook et al., Molecular Cloning: A Laboratory Manual, 4 th ed., Cold Spring Harbor Press, Plainsview, New York (2012); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 114), John Wiley & Sons, New York (2016). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in molecular biology, biochemistry, structural biology, and / or computational biology).
[0035] The terms "protein", "polypeptide" and "peptide" are further used interchangeably herein to refer to a polymer of amino acid residues, as well as variants and synthetic analogs thereof. A "peptide" may also be referred to as a partial amino acid sequence derived from its original protein, illustratively after trypsin digestion. Thus, these terms apply to amino acid polymers in which one or more amino acid residues are synthetic non-naturally occurring amino acids, such as chemical analogs of the corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers. The terms also encompass post-translational modifications of polypeptides, such as glycosylation, phosphorylation, and acetylation. Based on the amino acid sequence and modifications, the mass or weight of the atoms or molecules of a polypeptide is expressed in (kilo)daltons (kDa). A "protein domain" is a distinct functional and / or structural unit in a protein. Usually, a protein domain is responsible for a specific function or interaction and contributes to the overall role of the protein. Domains may exist in various biological contexts, where similar domains can be found in proteins with different functions.
[0036] "Isolated" or "purified" means material that is substantially or essentially free from components that normally accompany it in its natural state.
[0037] A "homolog" or "homologs" of a protein encompasses peptides, oligopeptides, polypeptides, proteins, and enzymes that have amino acid substitutions, deletions, and / or insertions compared to the unmodified protein in question and that have similar biological and functional activity as the unmodified protein from which they are derived. As used herein, the term "amino acid identity" refers to the degree to which sequences are identical amino acid-for-amino acid over a comparison window. In this way, the "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions in both sequences where identical amino acid residues (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met are also referred to herein by one-letter code) are present to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity. As used herein, a "substitution" or "mutation" or "variant" results from the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides, respectively, compared to the amino acid or nucleotide sequence of a parent protein or fragment thereof. It is understood that a protein or fragment thereof may have conservative amino acid substitutions that do not substantially affect the activity of the protein.
[0038] One of the major complications of diabetes, affecting one in 10 people worldwide, is the development of chronic non-healing wounds. A contributing factor to dysregulated tissue repair is the continued presence of dead cells in the wound, which sustains inflammation. Here, we identify the membrane transporter Slc7a11 as a novel molecular "brake" on efferocytosis, the process by which dead cells are removed. Here, we show that Slc7a11 inhibition can accelerate diabetic wound healing. First, via transcriptomics of dendritic cells that phagocytose apoptotic cells, we noted the upregulation of several members of the Slc7 gene family. In subsequent functional studies, the cystine / glutamate antiporter Slc7a11 emerged as a negative regulator of efferocytosis, with pharmacological inhibition, siRNA knockdown, or genetic deletion of Slc7a11 enhancing apoptotic cell uptake by dendritic cells. Interestingly, Slc7a11 was most highly expressed in dermal dendritic cells, and scRNAseq of inflamed skin showed upregulation of Slc7a11 in innate immune cells. In a mouse model of excision skin wounds, we found that loss or silencing of Slc7a11 expression accelerated healing kinetics and reduced apoptotic cell load in wounds. Mechanistic studies pointed to a relationship between Slc7a11, glucose homeostasis, and diabetes: first, Slc7a11-deficient dendritic cells relied on glycogen store-derived aerobic glycolysis for their improved efferocytic properties; and, second, transcriptomics of efferocytic Slc7a11-deficient dendritic cells identified genes related to gluconeogenesis and diabetes. When we examined the role of Slc7a11 in the delayed wound healing associated with the diabetic state, Slc7a11 expression was upregulated in the skin of diabetic db / db mice, and Slc7a11 inhibition accelerated wound healing in db / db mice. This faster healing was associated with improved removal of apoptotic cells in the wound and release of the TGF-β family member GDF15 from efferocytic dendritic cells.Taken together, our data identify Slc7a11 as a negative regulator of efferocytosis and removing this obstacle can improve wound healing, with significant impact on chronic wound healing, such as diabetic wound healing.
[0039] The solute carrier family 7 member 11 (abbreviated as Slc7A11) gene encodes a member of a heteromeric sodium-independent anionic amino acid transport system that is highly specific for cysteine and glutamate. In this system, designated Xc(-), the anionic form of cysteine is transported in exchange for glutamate. Other names for Slc7a11 include solute carrier family 7 (anionic amino acid transporter light chain, Xc-system, member 11, calcium channel blocker resistance protein CCBR1, amino acid transport system Xc-, XCT, and cystine / glutamate transporter.
[0040] For the avoidance of doubt, the amino acid sequence of human Slc7a11 protein is depicted in SEQ ID NO:1. SEQ ID NO:1 - Amino acid sequence of human Scl7a11 protein NH2-mvrkpvvstiskggylqgnvngrlpslgnkeppgqekvqlkrkvtllrgvsiiigtiigagifispkgvl qntgsvgmsltiwtvcgvlslfgalsyaelgttikksgghytyilevfgplpafvrvwvelliirpaata vislafgryilepffiqceipelaiklitavgitvvmvlnsmsvswsariqifltfckltailiiivpgvmqlikgqtqnfkdafsgrdssitrlplafyygmyayagwfylnfvteevenpektiplaicismaivtigyvltnvayfttinaeelllsnavavtfserllgnfslavpifv alscfgsmnggvfavsrlfyvasreghlpeilsmihvrkhtplpavivlhpltmimlfsgdldsllnflsfarwlfiglavagliylrykcpdmhrpfkvplfipalfsftclfmvalslysdpfstgigfvitltgvpayylfiiwdkkprwfrimsekitrtlqiilevvpeedkl-COOH
[0041] Thus, in a first aspect, the present invention provides a combination of an inhibitor of Slc7a11 and an apoptotic cell. In yet another aspect, the present invention provides a combination of an inhibitor of Slc7a11 and an apoptotic cell for use as a medicament.
[0042] In yet another embodiment, the present invention provides a combination of an inhibitor of Slc7a11 and apoptotic cells for use in treating wound healing. In yet another aspect, the present invention provides for an inhibitor of Slc7a11 for use in treating chronic wound healing in a mammal.
[0043] As used herein, the term "wound" includes any injury to tissue, including, for example, acute, delayed, or difficult to heal wounds, and chronic wounds. Examples of wounds may include both open and closed wounds. Wounds include, for example, burns, incisions, excisions, lacerations, abrasions, puncture to penetration wounds, surgical wounds, contusions, hematomas, crushing wounds, and ulcers. Also included are wounds that do not heal at the expected rate, as would be expected in diabetic patients. The term "wound" may also include, for example, injuries to dermal and subcutaneous tissues that are initiated in different ways (e.g., pressure sores from prolonged bed rest, and wounds induced by trauma) and have various characteristics. Wounds may be classified into one of four grades depending on the depth of the wound: (i) Grade I: wounds confined to the epithelium; (ii) Grade II: wounds extending into the dermis; (iii) Grade III: wounds extending into the subcutaneous tissue; and (iv) Grade IV (or full thickness wounds): wounds in which bone is exposed (e.g., bony pressure points such as the greater trochanter or sacrum).
[0044] The term "partial thickness wound" refers to wounds ranging from Grade I to Grade III; examples of partial thickness wounds include pressure ulcers, venous stasis ulcers, and diabetic ulcers. The present invention contemplates treating all types of wounds that do not heal at an expected rate, including delayed healing wounds, incomplete healing wounds, and chronic wounds.
[0045] By "wounds that do not heal at an expected rate" is meant any injury to tissue that does not heal within an expected or typical time frame, including delayed or difficult wound healing (including delayed or incomplete healing wounds) and chronic wounds. Examples of wounds that do not heal at an expected rate include ulcers such as diabetic ulcers, vasculitic ulcers, arterial ulcers, venous ulcers, venous stasis ulcers, burn ulcers, infectious ulcers, trauma-induced ulcers, pressure ulcers, decubitus ulcers, ulcerations associated with pyoderma gangrenosum, and mixed ulcers. Other wounds that do not heal at an expected rate include dehiscent wounds.
[0046] As used herein, delayed or difficult wound healing may include, for example, wounds that are characterized, at least in part, by (1) a prolonged inflammatory phase, (2) a slowly forming extracellular matrix, and / or (3) a reduced rate of epithelialization or closure.
[0047] The term "chronic wound" refers to a wound that does not heal. For example, a wound that does not heal within 6 weeks is considered to be chronic. Chronic wounds include, for example, diabetic ulcers, including pressure ulcers, bedsore ulcers, diabetic foot and leg ulcers, slow or non-healing venous ulcers, venous stasis ulcers, arterial ulcers, vasculitic ulcers, burn ulcers, trauma-induced ulcers, infectious ulcers, mixed ulcers, and pyoderma gangrenosum. Chronic wounds may be arterial ulcers, including ulcers resulting from complete or partial arterial occlusion. Chronic wounds may be venous or venous stasis ulcers, including ulcers resulting from venous valve insufficiency and associated vascular disease.
[0048] As used herein, the term "dehiscent wound" refers to a ruptured or dehiscent opening, usually a surgical wound. In certain embodiments, methods are provided for treating wounds that do not heal at an expected rate, where the wound is characterized by dehiscence.
[0049] In addition to the definitions previously provided, the term "wound" may also encompass, for example, injuries to cutaneous and subcutaneous tissues that are initiated in different ways (e.g., pressure ulcers due to prolonged bed rest and wounds induced by trauma) and have various characteristics.
[0050] In certain embodiments, the inhibitor for use in treating chronic wound healing in a mammal is selected from a small compound, an antibody, a gapmer, an shRNA, a synthetic siRNA, an antisense oligonucleotide selected from locked nucleic acid (LNA), peptide nucleic acid (PNA), or morpholino, CRISPR, TALEN, or zinc finger nuclease targeted to slc7a11.
[0051] In a further embodiment, the chronic wound healing is diabetic wound healing, arterial or venous wound healing, or pressure wound. The majority of chronic wounds fall into three main categories: venous and arterial ulcers, pressure ulcers, and diabetic ulcers (see Zhao R. et al (2016) Int. J. Mol. Sci. 17, 2085). In yet another aspect, the present invention provides a pharmaceutical composition comprising an inhibitor of Slc7a11 for use in treating chronic wounds.
[0052] System Xc- can be inhibited by many small molecules known in the art. Small chemical molecules such as erastin, sulfasalazine, and sorafenib can inhibit system Xc-function and induce ferroptosis. Other molecules that have been described to inhibit Xc- (approved for some conditions) are riluzole, cystine, glutamic acid, and acetylcysteine. Still other small molecules that inhibit system Xc- are the substituted N-acetyl-L-cysteine derivatives described in the claims of EP 3066089B1.
[0053] A cellular assay for monitoring the effect of inhibitors of the Xc-system is, for example, the measurement of cystine uptake. Cystine uptake levels can be measured as a convenient assay for monitoring the inhibition of Slc7A11 activity. Cystine uptake can be analyzed, for example, according to the sodium nitroprusside-based protocol previously described by Y. Gu et al (2017) Mol. Cell 67, 128-138.e7 (2017). Optionally, monitoring of cystine uptake is performed in parallel by measuring glutamate secretion, which can be quantified using various assays, such as the Glutamate-Glo assay sold by Promega.
[0054] Mammals include humans, pets (eg, dogs and cats), veterinary animals (eg, horses, pigs, cows), farm animals, and research animals.
[0055] DNA and RNA inhibitors of the Slc7a11 gene In a particular embodiment, the object of the present invention is to provide inhibitors of the functional expression of Slc7A11 target genes. Such inhibitors can act at the DNA level, at the RNA (i.e., gene product) level.
[0056] If inhibition is to be achieved at the DNA level, this may be done using gene therapy to knock out or disrupt the Slc7A11 target gene. As used herein, "knockout" can be gene knockdown, or the gene can be knocked out by mutations such as point mutations, insertions, deletions, frameshifts, or missense mutations, by techniques known in the art, including but not limited to retroviral gene transfer. Another way in which the gene can be knocked out is by using zinc finger nucleases. Zinc-finger nucleases (ZFNs) are artificial restriction enzymes produced by fusing zinc finger DNA binding domains to DNA cleavage domains. The zinc finger domains can be engineered to target desired DNA sequences, allowing zinc finger nucleases to target unique sequences within complex genomes. By utilizing endogenous DNA repair mechanisms, these reagents can be used to precisely modify the genome of higher organisms. Other techniques for genome customization that can be used to knock out genes are meganucleases and TAL effector nucleases (TALEN, Cellectis bioresearch). TALENs consist of a TALE DNA binding domain for sequence-specific recognition fused to the catalytic domain of an endonuclease that introduces a double strand break (DSB). The DNA binding domain of TALENs allows for high precision targeting of large recognition sites (illustratively 17 bp). Meganucleases are sequence-specific endonucleases that are naturally occurring "DNA scissors" originating from a variety of single-cell organisms such as bacteria, yeast, algae, and some plant organelles. Meganucleases have long recognition sites of 12-30 base pairs. The recognition sites of natural meganucleases can be modified to target natural genomic DNA sequences (such as endogenous genes).
[0057] Another recent genome editing technology is the CRISPR / Cas system, which can be used to achieve RNA-guided genome editing. CRISPR interference is a genetic technology that allows sequence-specific control of gene expression in prokaryotic and eukaryotic cells. CRISPR interference is based on the CRISPR (clustered regularly interspaced palindromic repeats) pathway from the bacterial immune system.
[0058] Gene inactivation, i.e., inhibition of the functional expression of a gene, may also be achieved, for example, through the creation of a transgenic organism that expresses the antisense RNA or by administering the antisense RNA to a subject. The antisense construct can be delivered, for example, as an expression plasmid, which, when transcribed in the cell, produces RNA complementary to at least a unique portion of the cellular Slc7a11 RNA.
[0059] A more rapid method for inhibiting gene expression is based on the use of shorter antisense oligomers made of DNA or other synthetic structural types such as phosphorothioates, 2'-0-alkyl ribonucleotide chimeras, locked nucleic acids (LNA), peptide nucleic acids (PNAs), or morpholinos. Except for RNA oligomers, PNAs, and morpholinos, all other antisense oligomers act in eukaryotic cells through the mechanism of RNase H-mediated target cleavage. PNAs and morpholinos bind to complementary DNA and RNA targets with high affinity and specificity, thus acting through simple steric blocking of the RNA translation machinery, and appear to be completely resistant to nuclease attack. "Antisense oligomer" refers to an antisense molecule or antigene agent that comprises an oligomer of at least about 10 nucleotides in length. In embodiments, antisense oligomers comprise at least 15, 18, 20, 25, 30, 35, 40, or 50 nucleotides. The antisense approach involves the design of oligonucleotides (either DNA or RNA, or their derivatives) that are complementary to the RNA encoded by the polynucleotide sequence of Slc7a11. Antisense RNA may be introduced into cells to inhibit the translation of complementary mRNA by base pairing to it and physical interference with the translational machinery. Thus, the effect is stoichiometric. Absolute complementarity, although preferred, is not required. The sequence "complementarity" to a portion of RNA referred to herein means a sequence that is capable of hybridizing with the RNA and has sufficient complementarity to form a stable duplex; thus, in the case of a double-stranded antisense polynucleotide sequence, a single strand of the duplex DNA may be tested or triplex formation may be assayed. The ability to hybridize depends on both the degree of complementarity and the length of the antisense polynucleotide sequence. Generally, the longer the hybridizing polynucleotide sequence, the more base mismatches it may contain with RNA and still form a stable duplex (or may be a triplex).Those skilled in the art can confirm the acceptable degree of mismatch by using standard procedures to determine the melting temperature of the hybridized complex.Antisense oligomers should be at least 10 nucleotides in length, and are preferably oligomers ranging from 15 nucleotides to about 50 nucleotides in length.In certain embodiments, the oligomers are at least 15 nucleotides in length, at least 18 nucleotides in length, at least 20 nucleotides in length, at least 25 nucleotides in length, at least 30 nucleotides in length, at least 35 nucleotides in length, at least 40 nucleotides in length, or at least 50 nucleotides in length.
[0060] Related methods use ribozymes instead of antisense RNA. Ribozymes are catalytic RNA molecules with enzyme-like cleavage properties that can be designed to target specific RNA sequences. Successful targeted gene inactivation, including time- and tissue-specific gene inactivation, using ribozymes has been reported in mice, zebrafish, and Drosophila. RNA interference (RNAi) is a form of post-transcriptional gene silencing. The phenomenon of RNA interference was first observed and described in Caenorhabditis elegans, where it was shown that exogenous double-stranded RNA (dsRNA) specifically and potently disrupts the activity of genes containing homologous sequences through a mechanism that induces rapid degradation of the target RNA. Several reports have described the same catalytic phenomenon in other organisms, including experiments demonstrating spatial and / or temporal control of gene inactivation, including plant species (Arabidopsis thaliana), protozoan species (Trypanosoma brucei), invertebrate species (Drosophila melanogaster), and vertebrate species (Danio rerio and Xenopus laevis). The mediators of sequence-specific messenger RNA degradation are small interfering RNAs (siRNAs) produced by ribonuclease III cleavage from longer dsRNAs. Generally, siRNAs are 20-25 nucleotides in length (Elbashir et al. (2001) Nature 411,494 498). siRNAs typically contain a sense RNA strand and a complementary antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter "base pairing"). The sense strand contains a nucleic acid sequence identical to the target sequence contained within the target mRNA.The sense strand and antisense strand of the siRNA of the present invention can comprise two complementary single-stranded RNA molecules, or can comprise a single molecule in which two complementary portions are base-paired and covalently linked by a single-stranded "hairpin" section (often referred to as shRNA). The term "isolated" means that it is modified or removed from its natural state by human intervention. For example, siRNA that naturally exists in a living animal is not "isolated", but synthetic siRNA, or siRNA that is partially or completely separated from its natural state of coexisting materials, is "isolated". Isolated siRNA can exist in a substantially purified form or can exist in a non-native environment (such as, for example, a cell into which the siRNA is delivered).
[0061] The siRNA of the invention can include partially purified RNA, substantially pure RNA, synthetic RNA, or recombinantly produced RNA, as well as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution, and / or modification of one or more nucleotides. Such modifications can include the addition of non-nucleotide material, such as to the termini (both ends) of the siRNA or to one or more internal nucleotides of the siRNA, including modifications that render the siRNA resistant to nuclease digestion.
[0062] One or both strands of the siRNA of the present invention may also comprise a 3' overhang. "3' overhang" refers to at least one unpaired nucleotide extending from the 3' end of an RNA strand. Thus, in one embodiment, the siRNA of the present invention comprises at least one 3' overhang that is 1 to about 6 nucleotides long (including ribonucleotides or deoxynucleotides), preferably 1 to about 5 nucleotides long, more preferably 1 to about 4 nucleotides long, and particularly preferably about 1 to about 4 nucleotides long.
[0063] In the embodiment in which both strands of siRNA molecule contain 3' overhang, the length of overhang can be the same or different for each strand.In the most preferred embodiment, 3' overhang is present on both strands of siRNA and is 2 nucleotides long.To enhance the stability of siRNA of the present invention, 3' overhang can also be stabilized against degradation.In one embodiment, overhang is stabilized by including purine nucleotide such as adenosine or guanosine nucleotide.
[0064] Alternatively, substitution of pyrimidine nucleotides with modified analogs, such as substitution of uridine nucleotides in the 3' overhangs with 2' deoxythymidine, is tolerated and does not affect the efficiency of RNAi degradation. In particular, the absence of a 2' hydroxyl in the 2' deoxythymidine significantly enhances the nuclease resistance of the 3' overhangs in tissue culture medium.
[0065] The siRNA of the present invention can be targeted to any stretch of approximately 19-25 contiguous nucleotides in any of the target Slc7a11 RNA sequences ("target sequences"), examples of which are provided in this application. Techniques for selecting siRNA target sequences are well known in the art. Thus, the sense strand of the siRNA of the present invention contains a nucleotide sequence identical to any contiguous stretch of approximately 19-25 nucleotides in the target mRNA.
[0066] The siRNA of the present invention can be obtained using several techniques known to those skilled in the art. For example, siRNA can be chemically synthesized or recombinantly produced using methods known in the art. Preferably, the siRNA of the present invention is chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA / RNA synthesizer. siRNA can be synthesized as two separate complementary RNA molecules or as a single RNA molecule with two complementary regions. Commercial suppliers of synthetic RNA molecules or synthesis reagents include Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, Colo., USA), Pierce Chemical (a division of Perbio Science, Rockford, Ill., USA), Glen Research (Sterling, Va., USA), ChemGenes (Ashland, Mass., USA), and Cruachem (Glasgow, UK).
[0067] Alternatively, siRNA can also be expressed from recombinant circular or linear DNA plasmids using any suitable promoter.Suitable promoters for expressing siRNA of the present invention from plasmids include, for example, U6 or H1 RNA pol III promoter sequences and cytomegalovirus promoters.The selection of other suitable promoters is within the scope of the art.Recombinant plasmids of the present invention can also include inducible or regulatable promoters for the expression of siRNA in specific tissues or specific intracellular environments.The siRNA expressed from recombinant plasmids can either be isolated from cultured cell expression systems by standard techniques or expressed intracellularly, for example in breast tissue or neurons.
[0068] The siRNA of the present invention can also be expressed intracellularly from a recombinant viral vector.The recombinant viral vector comprises a sequence encoding the siRNA of the present invention and any suitable promoter for expressing the siRNA sequence.Suitable promoters include, for example, U6 or H1 RNA pol III promoter sequences and cytomegalovirus promoters.The selection of other suitable promoters is within the skill of the art.The recombinant viral vector of the present invention can also comprise an inducible or regulatable promoter for the expression of siRNA in tissues where tumors are localized.
[0069] As used herein, the "effective amount" of siRNA refers to the amount sufficient to cause the RNAi-mediated degradation of target mRNA or to inhibit the progression of metastasis in subject.The RNAi-mediated degradation of target mRNA can be detected by measuring the level of target mRNA or protein in the cells of subject, using standard techniques for isolating and quantifying mRNA or protein as described above.
[0070] Those skilled in the art can easily determine the effective amount of the siRNA of the present invention to be administered to a given subject by considering factors such as the size and weight of the subject; the degree of disease penetration; the age, health, and sex of the subject; the route of administration; and whether the administration is regional or systemic. In general, an effective amount of the siRNA of the present invention includes an intracellular concentration of about 1 nanomolar (nM) to about 100 nM, preferably about 2 nM to about 50 nM, and more preferably about 2.5 nM to about 10 nM. It is contemplated that greater or lesser amounts of siRNA can be administered.
[0071] Recently, morpholino antisense oligonucleotides in zebrafish and frogs have been shown to overcome the limitations of RNase H-competent antisense oligonucleotides, including the numerous non-specific effects resulting from non-target specific cleavage of other mRNA molecules caused by the low stringency requirements of RNase H. Thus, morpholino oligomers represent an important new class of antisense molecules. The oligomers of the present invention may be synthesized by standard methods known in the art. For example, phosphorothioate oligomers may be synthesized by the method of Stein et al. (1988) Nucleic Acids Res. 16, 3209 3021), and methylphosphonate oligomers can be prepared by using controlled pore glass polymer supports (Sarin et al. (1988) Proc. Natl. Acad. Sci. USA. 85, 7448-7451). Morpholino oligomers may be synthesized by the methods of Summerton and Weller, US Pat. Nos. 5,217,866 and 5,185,444.
[0072] Another special form of antisense RNA strategy is the gapmer. A gapmer is a chimeric antisense oligonucleotide that contains a central block of deoxynucleotide monomers of sufficient length to induce RNase H cleavage. The central block of the gapmer is flanked by blocks of 2'-O modified ribonucleotides or other artificially modified ribonucleotide monomers such as bridged nucleic acid (BNA) that protect the internal blocks from nuclease degradation. Gapmers have been used to obtain RNase-H mediated cleavage of target RNA while decreasing the number of phosphorothioate linkages. Phosphorothioates possess increased resistance to nucleases compared to unmodified DNA. However, phosphorothioates have several drawbacks. These include low binding capacity to complementary nucleic acids and nonspecific binding to proteins that cause toxic side effects that limit their application. The occurrence of toxic side effects where nonspecific binding causes off-target effects together has stimulated the design of novel artificial nucleic acids for the development of modified oligonucleotides that provide efficient and specific antisense activity in vivo without toxic side effects. By recruiting RNase H, gapmers selectively cleave the target oligonucleotide strand. Cleavage of this strand initiates the antisense effect. This approach has proven to be a powerful method in inhibiting gene function and has emerged as a common approach for antisense therapy. Gapmers are commercially available, such as LNA longRNA GapmeR by Exiqon, or MOE gapmer by Isis pharmaceuticals. MOE gapmers or "2'MOE gapmers" are antisense phosphorothioate oligonucleotides of 15-30 nucleotides in which all of the backbone linkages are modified by adding sulfur to the non-bridging oxygen (phosphorothioate), and a stretch of at least 10 consecutive nucleotides remains unmodified (deoxy sugar), and the remaining nucleotides contain O'-methyl O'-ethyl substitutions at the 2' position (MOE).
[0073] Antibody that inhibits the activity of Slc7A11 Antibodies that specifically bind to Slc7a1, particularly antibodies that bind to the extracellular domain of Slc7a11, can inhibit the activity of Slc7a11, and such antibodies are intended for use in treating wound healing, particularly chronic wound healing, in mammals.
[0074] The term "antibody" as used herein refers to an immunoglobulin (Ig) molecule or a molecule containing an immunoglobulin (Ig) domain that specifically binds to Slc7a11, preferably at the extracellular domain of Slc7a11. An "antibody" can also be an intact immunoglobulin from natural or recombinant sources, and can be an immunoreactive portion of an intact immunoglobulin. The term "active antibody fragment" refers to any antibody or antibody-like structure that has high affinity for an antigenic determinant or epitope and contains one or more CDRs that account for such specificity. Non-limiting examples include immunoglobulin domains, Fab, F(ab)'2, scFv, heavy-light chain dimers, immunoglobulin single variable domains, nanobodies, domain antibodies, and single chain structures such as complete light chains or complete heavy chains. Examples of antibodies that specifically bind to an extracellular epitope of Slc7a11 and inhibit the activity of Slc7a11 are taught in WO 2018 / 204278 and WO 2020 / 227640.
[0075] combination In certain embodiments, combinations of inhibitors of Slc7a11 with other molecules for use in treating wound healing, particularly chronic wound healing, are envisaged. Although the inhibition of Slc7a11 is sufficient to achieve a therapeutic effect, i.e., to achieve wound healing, particularly chronic wound healing, it is shown herein in the accompanying Examples section that when both an inhibitor of Slc7a11 and growth factor GDF-15 are administered, a stronger synergistic effect is achieved. The synergistic effect can be obtained by simultaneous, combined, separate, or sequential use to treat wound healing, particularly chronic wound healing.
[0076] In yet another aspect, the present invention provides a composition comprising an inhibitor of Slc7a11 and GDF-15 for use as a medicament. In yet another aspect, the present invention provides a composition comprising an inhibitor of Slc7a11 and GDF-15 for use in treating wound healing, particularly chronic wound healing, in a mammal.
[0077] Pharmaceutical Compositions The present invention also relates to pharmaceutical compositions containing one or more compounds of the present invention for use in treating wound healing, particularly chronic wound healing. These compositions can be utilized to achieve a desired pharmacological effect by administration to a mammal, such as a patient in need thereof. For the purposes of the present invention, a patient is a mammal, including a human, in need of treatment of a particular condition or disease. Thus, the present invention includes pharmaceutical compositions for use in treating wound healing, particularly chronic wound healing, comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of the present invention or a salt thereof. A pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and harmless to a patient at a concentration consistent with the effective activity of the active ingredient, such that any side effects attributable to the carrier do not negate the beneficial effects of the active ingredient. A pharmaceutically effective amount of a compound is preferably an amount that results in or affects the particular condition being treated. The compounds of the present invention may be administered orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like, using any effective conventional dosage unit form, including immediate release, sustained release, and timed release preparations, with pharma- ceutically acceptable carriers well known in the art.
[0078] In a particularly preferred embodiment, administration is topical. Another formulation that can be employed in the present invention is a transdermal delivery device ("patch"). Such transdermal patches can be used to provide continuous or discontinuous infusion of one or more inhibitors of Slc7a11 in a controlled amount. The construction and use of transdermal patches to deliver pharmaceutical agents is well known in the art (see, for example, U.S. Patent No. 5,023,252). Such patches can be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents.
[0079] Dosage and Administration : Based on known standard laboratory techniques for evaluating compounds useful in the treatment of the diseases cited herein, standard toxicity tests, and standard pharmacological assays for determining the treatment of the above-identified conditions in mammals, and comparison of these results with those of known pharmaceuticals used to treat these conditions, the effective dosage of the compounds of the present invention can be easily determined for the treatment of the indications cited herein. The amount of active ingredient administered in the treatment can vary widely according to such considerations as the specific compound and dosage unit employed, the mode of administration, the duration of the treatment, the age and sex of the patient being treated, and the nature and extent of the condition being treated.
[0080] The total amount of active ingredient administered generally ranges from about 0.001 mg / kg to about 200 mg / kg body weight per day, preferably from about 0.01 mg / kg to about 50 mg / kg body weight per day. Clinically useful dosing schedules range from one to three times a day to once every four weeks. In addition, a "drug holiday" during which the patient does not receive the drug for a certain period of time may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dose may contain from about 0.5 mg to about 1500 mg of active ingredient and may be administered more than once a day, or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous, and parenteral injections, as well as the use of infusion techniques, will preferably be 0.01 to 200 mg / kg of total body weight. The average daily rectal dosing regimen will preferably be 0.01 to 200 mg / kg of total body weight. The average daily vaginal dosage regimen will preferably be 0.01-200 mg / kg of total body weight. The average daily topical dosage regimen will preferably be 0.1-200 mg administered 1-4 times per day. The transdermal concentration will preferably be that required to maintain a daily dose of 0.01-200 mg / kg. The average daily inhalation dosage regimen will preferably be 0.01-100 mg / kg of total body weight. The average daily oral dosage regimen will preferably be 0.01-100 mg / kg of total body weight.
[0081] It will be apparent to one skilled in the art that the particular initial and continuing dosing regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the particular compound employed, the age and general condition of the patient, the time of administration, the route of administration, the rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and frequency of administration of the compounds of the invention or their pharmacologic acceptable salts or esters or compositions can be ascertained by one skilled in the art using conventional treatment trials.
[0082] Although specific embodiments, specific configurations, and materials and / or molecules are discussed herein for the cells and methods according to the present invention, it should be understood that various changes or modifications in form and details may be made without departing from the scope and spirit of the invention. The following examples are provided to better illustrate certain embodiments and should not be considered as limiting the present application. The present application is limited only by the claims.
[0083] example 1. Upregulation of amino acid transporters in dendritic cells phagocytosing apoptotic cells The gene signature initiated in dendritic cells during efferocytosis has yet to be defined, and the adaptation of dendritic cells to the metabolic challenge of ingesting cargo remains unclear. To address this, we incubated primary mouse bone marrow dendritic cells (BMDC phagocytes) with apoptotic human Jurkat cells, purified efferocytic dendritic cells, and performed RNAseq analysis (Figure 1a). Using this cross-species approach, we easily distinguished mouse phagocytic RNA from any apoptotic cargo-derived RNA. We also used plain beads as targets to control phagocytosis. In our analysis, we focused on differentially expressed genes associated with "transporter" activity, based on the initial hypothesis that dendritic cells may have molecular features that differ from other phagocytes with respect to how they perceive and interpret ingested apoptotic cargo. We found significant alterations in genes encoding membrane transporters with diverse functions, including those that pass ions, lipids, and amino acids (Figure 1b). Interestingly, the solute carrier (Slc) family of genes represented 29% of the transporters differentially expressed in efferocytic dendritic cells (Figure 1c). SLCs represent the second largest gene family in the human genome (after GPCRs) and are composed of membrane proteins that mediate the transport of metabolites and solutes across cell membranes. SLCs are implicated in over 100 human diseases, are amenable to targeting by small molecules, and are a promising new class of transporters that are highly expressed in other phagocytes. 21 SLCs encoding amino acid metabolism and carbohydrate catabolism were upregulated in efferocytic dendritic cells, whereas SLCs involved in oxidative phosphorylation (OXPHOS) and fatty acid transport were downregulated (Fig. (Fig.5a).5a).
[0084] Amino acid transport is essential for nutritional supply, and dendritic cells 24 Immune cells, including 22、23Thus, we chose to focus on several Slc7 family members. 25 We examined cationic (Slc7a1–Slc7a4) and heterodimeric amino acid transporters (Slc7a5–Slc7a11), as well as Slc3a2, which chaperone / help drive plasma membrane localization of EF. Among Slc7 family members, efferocytic dendritic cells had the greatest increase in Slc7a5 and Slc7a11 (Figure 1d).
[0085] 2. Slc7a11 antiporter acts as a brake on efferocytosis by dendritic cells To test the relevance of these amino acid transporters upregulated in efferocytic BMDCs, we performed siRNA-mediated knockdown in BMDCs, followed by efferocytosis via flow cytometry-based assays, and an independent live-cell imaging assay for apoptotic cell uptake over time. Among the Slc7 family members we targeted via siRNA, disrupting Slc7a11 expression consistently and significantly increased efferocytosis by dendritic cells (Figure 1e). Slc7a11, also known in the literature as xCT, is a cystine-glutamate antiporter system X that regulates the exchange of intracellular glutamate for extracellular cystine. c -, the latter being the rate-limiting precursor for the synthesis of the antioxidant glutathione (GSH). Slc7a11 has also been shown to be a promising treatment for neurological disorders, with drugs targeting Slc7a11 being tested in clinical trials. 26~28、29、30 , viral infection 31、32、33 , and multiple cancers 34、35、36Under these conditions, knockdown of Slc7a1 had no effect on BMDC efferocytosis, whereas knockdown or pharmacological inhibition of Slc7a5 only showed a trend toward more efferocytosis, which was not statistically significant (Figure 5b-Figure 5e). We were initially surprised to find that Slc7a11 acts as a negative regulator of efferocytosis, as its expression is strongly elevated during efferocytosis. Therefore, we took additional pharmacological and genetic approaches to address the role of Slc7a11 in dendritic cell efferocytosis. The drug erastin 37 Inhibition of Slc7a11 by erastin caused a dramatic boost in efferocytosis (Fig. 1f); in contrast, erastin had no effect on the phagocytosis of E. coli bioparticles by dendritic cells (Fig. 6a). Elastin has been described as a ferroptosis inducer in cancer cells. 38、39、40 Nevertheless, the enhanced efferocytosis in dendritic cells was not associated with ferroptosis, and another known ferroptosis-inducing compound, ML-162, was not associated with ferroptosis. 38 did not enhance efferocytosis (Fig. 6b). Elastin treatment reduced intracellular glutathione levels (Fig. 6c), while only slightly increasing lipid ROS accumulation (Fig. 6e) and not affecting dendritic cell viability (Fig. 6d). The effect of erastin could also be mimicked by adding excess glutamate to "block" Slc7a11-mediated cystine uptake, which also boosted efferocytosis (Extended Fig. 2f).
[0086] As a genetic approach, we tested different types of dendritic cells from Slc7a11-deficient mice. Comparing purified primary splenic conventional dendritic cells from control and Slc7a11-deficient mice, we observed enhanced uptake by Slc7a11-deficient cDC1 but not cDC2. Similarly, ex vivo-generated BMDCs lacking Slc7a11 displayed greater efferocytosis compared to controls (Figure 1g, Figure 1h, Figure 1i). This enhanced efferocytosis by Slc7a11-deficient dendritic cells was seen with apoptotic targets labeled with either pH-insensitive (TAMRA) or pH-sensitive (CypHer5E) reporter dyes (Figure 1i), which was abrogated by blocking cytoskeletal rearrangements with cytochalasin D (Figure 1h, Figure 1i). The increased uptake scored in these assays was not due to incomplete digestion of apoptotic corpses, as Slc7a11-deficient dendritic cells showed corpse degradation (measured by CellTrace Violet labeling of apoptotic cells) similar to wild-type dendritic cells (Figure 5F). Supporting specificity for the effect of erastin on Slc7a11 in this assay, there was no additive increase in the efferocytic capacity of Slc7a11-deficient dendritic cells treated with erastin (Figure 1H). Interestingly, neither bone marrow-derived macrophages from Slc7a11-deficient mice nor peritoneal macrophages from wild-type mice treated with erastin showed enhanced efferocytosis under these conditions (Figure 5G-H). Finally, Slc7a11-deficient dendritic cells did not show enhanced uptake of “live” cells (Figure 1I). Taken together, these data suggest that Slc7a11 acts as a brake on dendritic cell efferocytosis.
[0087] 3. Cutaneous wound healing is accelerated in the setting of Slc7a11 blockade The presence of unwashed apoptotic cells is often associated with chronic inflammation. 41Therefore, we wanted to address the physiological relevance of enhanced efferocytosis resulting from loss or inhibition of Slc7a11. First, we evaluated the gene expression profile of SLCs in resident dendritic cell subsets of the spleen, lung, or skin. Mining from publicly available datasets (ImmGen) and tri-wise comparisons, we found that the Slc7a11 gene is most highly expressed in skin-resident dendritic cells compared to DCs from the spleen or lung (Figure 2a). In contrast, Slc7a5 is more highly expressed in splenic and lung DCs. Previous studies have shown that Langerin (located in the epidermis) is a key regulator of efferocytosis in spleen, lung, or skin. + Cell depletion enhances cutaneous wound healing 42 On the other hand, dermal CD11c (located in the dermis) + suggested that depletion of dendritic cells delayed wound closure. 43 Therefore, we next addressed the relationship between Slc7a11 and dendritic cells during skin regeneration. When we tested purified dermal dendritic cells isolated from the ears of Slc7a11-deficient mice, cDC1 cells showed enhanced efferocytosis compared to that from wild-type mice; in comparison, Langerhans cells and cDC2 were poor phagocytes ex vivo, and their phagocytic capacity was not altered by Slc7a11 deficiency (Fig. 2b, Fig. 7a). CD64 陽性 Macrophages were potent in engulfing apoptotic cells, whereas Slc7a11 deficiency did not alter their engulfment (Fig. 2b). Histological analysis of wound skin tissue biopsies showed that Slc7a11 colocalized with the DC marker CD11c (Fig. 2c), but not with fibroblasts (Fig. 7b). Moreover, CD11c + Dendritic cells express cleaved caspase-3 + As shown by staining, it appeared to be proximal to and capture apoptotic corpses (Fig. 2d).We also noted increased Slc7a11 expression in whole skin lysates after full thickness wounding, along with increased expression of wound-related genes such as Tgfb1 and Tnf (Fig. 2f).
[0088] Next, we tested whether disrupting Slc7a11 function might affect skin wound healing kinetics. We administered a metabolically stable, water-soluble version of elastin (termed IKE) to mice following full-thickness skin wounding (days 0-2). 45、46 However, administration of elastin alone to inhibit Slc7a11 at the wound site did not improve wound healing (Fig. 7f). Previous studies from many groups have suggested that efferocytic phagocytes provide many beneficial factors in suppressing inflammation. 2、3、4、5 Therefore, we sought to determine whether it might be beneficial to co-administer some early stage apoptotic cells together with elastin. Remarkably, a single administration of apoptotic cells (in the form of apoptotic Jurkat cells) on day 0 together with elastin on days 0 and 2 to the wound site (hereafter referred to as the "elastin regimen") significantly accelerated wound healing (Fig. 2g, Fig. 7e), resulting in more rapid and complete closure of the initial wound (Fig. 2h). Wound closure in the elastin-treated mice reached 50% of wound closure on day 4 post-wounding, nearly 2 days earlier than the respective controls (Fig. 2g). Importantly, administration of apoptotic cells alone without elastin did not improve the kinetics of wound closure (Fig. 7f). Elastin regimen-mediated Slc7a11 inhibition greatly reduced the apoptotic cell burden in the wound site, as evidenced by fewer cells staining positive for cleaved caspase-3 (Fig. 2i). Thus, accelerated wound healing requires a bolus of early-stage apoptotic cells combined with erastin-mediated Slc7a11 inhibition, the latter of which improves efferocytosis at the wound site. 40、47The benefit of this elastin regimen was not associated with induction of ferroptosis in the skin, since elastin (given together with apoptotic cells) did not improve wound healing (Figure 7g). To test the elastin regimen on existing wounds, we administered elastin on days 2-4 after wounding, which also resulted in faster healing after skin wounding (Figure 2j).
[0089] To complement the above studies with genetic approaches, we tested Slc7a11-deficient mice (Fig. 2k). Slc7a11-deficient mice also showed accelerated wound healing kinetics, which also required the simultaneous administration of apoptotic cells on day 0 after wounding. Wound closure in Slc7a11-null mice also reached 50% wound closure almost 2 days earlier than the respective controls (Fig. 2g and Fig. 2k). These data strongly suggest that disruption of Slc7a11 function in the presence of apoptotic cells can accelerate skin wound healing.
[0090] 4. Glycogen Storage and Aerobic Glycolysis Fuel Enhanced Efferocytosis in Dendritic Cells We were intrigued by the idea that the combination of Slc7a11 inhibition and apoptotic cells accelerated cutaneous wound healing, while neither of them had much of a significant effect alone. To better understand how Slc7a11 loss / inhibition synergizes with apoptotic cells, we performed RNAseq analysis of control and Slc7a11-deficient dendritic cells phagocytosing apoptotic cells (Figure 3a). There were few basal differences in gene expression between WT and Slc7a11 KO dendritic cells, while efferocytic Slc7a11-deficient dendritic cells had 191 differentially expressed genes (125 up-regulated and 66 down-regulated) compared to control efferocytic dendritic cells. Literature analysis of these genes for association with specific pathways indicated that the differentially expressed genes represent biological processes encompassing metabolism, protein synthesis, mitochondrial and ER function, transcriptional regulation, and wound healing (Figure 3b, Figure 8a). Metabolic functions were the most represented transcriptional programs initiated in Slc7a11-deficient compared to WT efferocytic dendritic cells, followed by gluconeogenesis (Gpt2, Dyrk1b, Hlcs, Pck2). 48、49 , diabetes and obesity (Gdf15, Pck2) 50、51、52 , and harbored genes related to amino acid synthesis (Asns, Phgdh), glutamate metabolism (Aldh18a1, Psat1, Gpt2, Got1), and lipid metabolism (Cyb5r1, Soat2, Acaa1b, Cd5l).
[0091] It has previously been shown in macrophages that aerobic glycolysis of glucose is important for the initial uptake and for the continued uptake of additional apoptotic corpses. 21 Dendritic cells are unique among phagocytes in that they possess intracellular glycogen stores. 53Interestingly, a gene related to gluconeogenesis (i.e., production of glucose) emerged as one of the top hits in RNAseq of Slc7a11-deficient efferocytic dendritic cells compared to WT dendritic cells. Thus, we considered the intriguing possibility that Slc7a11-deficient dendritic cells may have an increased capacity to convert part of their glycogen stores to produce more glucose, which in turn may be used for aerobic glycolysis, achieving increased efferocytosis. We first assessed whether glycogen stores differed between control and Slc7a11-deficient dendritic cells, and between WT dendritic cells before and after elastin treatment. Both Slc7a11-deficient BMDCs and elastin-treated wild-type cDC1s showed a decrease in intracellular glycogen (Figure 3c). Importantly, the addition of the glycogen phosphorylase inhibitor CP-91149 nearly reversed glycogen levels in elastin-treated BMDCs relative to DMSO controls (Figure 3d). We then asked whether glycogenolysis was important for the increased efferocytosis following Slc7a11 inhibition. The addition of CP-91149 strongly abrogated the elastin-dependent increase in efferocytosis (Figure 3d), supporting the idea that glycogenolysis contributes to greater DC efferocytosis.
[0092] Next, we sought to determine whether aerobic glycolysis is important for efferocytosis in dendritic cells. In Seahorse analysis, Slc7a11-deficient or elastin-treated dendritic cells showed greater aerobic glycolysis (ECAR) and reduced oxygen consumption rate (OCR, suggestive of mitochondrial oxidative phosphorylation), accompanied by a significant decrease in spare respiratory capacity (Fig. 3e and Fig. 9a). During efferocytosis, both WT and elastin-treated dendritic cells showed greater aerobic glycolysis (ECAR) and less OCR (Fig. 3e). To test whether aerobic glycolysis plays a role in the enhanced efferocytosis by Slc7a11-deficient dendritic cells, we used several pharmacological inhibitors. First, the non-metabolizable glucose analog 2-deoxyglucose (2-DG) abrogated the enhanced efferocytosis caused by Slc7a11 inhibition (Fig. 3f). Moreover, the cell-permeable pyruvate derivative 3-bromopyruvate (3-BP), which acts as an inhibitor of hexokinase-II-mediated glycolysis (Fig. 3f), also abrogated the enhanced inhibition caused by erastin treatment. This did not seem to be the case when we asked whether alternative fuel substrates such as glutamine or pyruvate could be used by Slc7a11-inhibited dendritic cells: a glutamine antagonist (DON) slightly reduced the erastin-mediated increased efferocytosis, whereas inhibiting pyruvate import into mitochondria (via the drug UK5099) had no effect on efferocytosis (Fig. 9c). Notably, none of the inhibitors interfered with dendritic cell viability (Figure (Figure9b). (Figure9b). Collectively, these data suggest that the conversion of glycogen stored in dendritic cells to glucose, and subsequent aerobic glycolysis, contributes to the enhanced efferocytosis by Slc7a11-deficient dendritic cells.
[0093] 5. Slc7a11 inhibition and rGDF15 promote wound healing in diabetic mice Non-healing chronic wounds are a serious complication that significantly affects the quality of life of diabetic patients. 54 To test the relevance of Slc7a11 to wound healing in the diabetic context, we used leptin receptor-deficient db / db mice, which represent a model of human type 2 diabetes accompanied by obesity and hyperglycemia. We first confirmed that wound healing was impaired in db / db mice in a skin excision model; wound healing in db / db mice was delayed by nearly 3 days to reach half-maximal closure (Figure 4a, and references ). 55 ). When we examined the level of Slc7a11 expression, it was notably 200-fold higher at day 4 in wounds of db / db mice compared to normoglycemic C57B / 6 mice (Fig. 4b). Next, we tested whether Slc7a11 inhibition might affect diabetic wound healing by treating db / db mice after wounding with elastin alone and with an elastin regimen (apoptotic cell coadministration). Unlike nondiabetic wounds, diabetic wounds treated with elastin alone presented accelerated closure (Fig. 4c), likely due to the presence of sufficient unwashed apoptotic cells in diabetic wounds. Indeed, wounds of C57B / 6 mice contained an average of 400 apoptotic cells (cleaved caspase 3) at day 4. + ) (Fig. 2i) and dropped to 50 by day 13, whereas diabetic wounds scored an average of 400 at day 13 reflecting an increased apoptotic load (Fig. 4c). The elastin regimen with apoptotic cells also provided significant improvement as early as day 2 post-wounding, which continued to complete closure by day 13. Notably, wounds in db / db mice treated via the elastin regimen reached 50% closure of the initial wound 2–3 days earlier than control mice (Fig. 4d).
[0094] We next examined the relationship between apoptotic cell clearance and accelerated wound closure due to elastin treatment in db / db mice. In ex vivo analyses, dendritic cells from diabetic mice showed reduced efferocytosis compared to wild-type controls, where the difference was more pronounced at earlier time points, similar to the defective effector cell expansion seen by macrophages from diabetic mice (Figure 4e). 13 Surprisingly, erastin treatment "rescued" the defective efferocytosis of diabetic db / db dendritic cells (Figure 4e) to the level of wild-type dendritic cells treated with erastin. Consistent with this ex vivo phenotype, the erastin regimen reduced uncleaved caspase 3 in wounds of db / db mice. + The number of apoptotic cells was substantially reduced (FIG. 4f).
[0095] The combination of Slc7a11 inhibition and the addition of apoptotic cells to the wound provided the most efficient wound healing, as efferocytic phagocytes also secrete factors known to provide beneficial effects to tissues. 56 Therefore, we sought to determine whether secreted factors from efferocytic Slc7a11-deficient dendritic cells might contribute to accelerated healing. We purified supernatants from efferocytic wild-type and Slc7a11 KO dendritic cells and added these exogenous supernatants to excision wounds. Mice treated with efferocytic supernatants from efferocytic Slc7a11-deficient dendritic cells exhibited faster wound closure compared to WT dendritic cells (Figure 4g).
[0096] Soluble factors, including members of the TGF-β superfamily (TGF-β 1-3), are produced by efferocytic phagocytes and are known to play important roles in various stages of wound healing. 57When we searched the transcriptome of efferocytic Slc7a1-deficient dendritic cells for TGF-β superfamily members, we noted that GDF15 was specifically upregulated (Fig. 4h). GDF15 was also significantly increased in the supernatant of efferocytic dendritic cells from Slc7a11-deficient mice compared to that of wild-type littermates (Fig. 4h). Growth differentiation factor-15 (GDF15) is a recently discovered member of the transforming growth factor β (TGF-β) superfamily that has been linked to obesity, diabetes, cancer, cardiovascular, and renal disorders. 50、58、59 During cutaneous wound healing, GDF15 levels increased (2-5 fold) at day 2 after excision skin wounding compared to unwounded skin and remained high even at the later stages of the healing process (day 8) (Figure 4i). We next tested GDF15-deficient mice in an excision skin biopsy model. GDF15 knockout mice presented larger wounds at day 2 compared to littermate control mice (Figure 4j), which correlated with greater Slc7a11 expression in the wound (Figure 4b). Consistent with the idea that GDF15 generates downstream efferocytosis, GDF15-deficient dendritic cells showed comparable efferocytosis to controls (Figure 10a). We next asked whether the addition of recombinant GDF15 (rGDF15) might also aid in wound healing in diabetic db / db mice. Indeed, application of rGDF15 significantly improved wound healing in db / db mice (Figure 4k). Collectively, these data suggest that Slc7a11 inhibition at the wound site can improve diabetic wound healing through at least two modalities: by reversing impaired cell clearance by dendritic cells and through secretion of factors such as GDF15 by efferocytic cells that promote wound healing.
[0097] 6. Discussion The data presented here advance new concepts regarding dendritic cell-mediated efferocytosis and its relevance to tissue regeneration / wound healing using a combination of in vitro, ex vivo, and in vivo approaches. First, we demonstrate that the expression of multiple membrane proteins and transporters is regulated during apoptotic cell phagocytosis by dendritic cells. Among these membrane proteins, the amino acid transporter Slc7a11 acts as a negative regulator of efferocytosis. It is unclear why this negative regulator of efferocytosis is upregulated after wounding, since inhibition or loss of Slc7a11 leads to improved wound healing in both nondiabetic and diabetic mice. Nevertheless, a similar simultaneous upregulation of negative and positive regulators (i.e., simultaneous pressing of the "accelerator" and "brake") is seen in T cells during antigen receptor signaling, in fibroblasts during growth factor stimulation, and in macrophages during FcR-mediated phagocytosis, and is likely part of a finely balanced signaling regulation in vivo. Mechanistically, enhanced efferocytosis in Slc7a11-deficient dendritic cells is fueled in part by greater aerobic glycolysis (where the source of glucose is derived from glycogen stores), a feature somewhat unique to dendritic cells among phagocytes.
[0098] The present invention also reveals dendritic cells as relevant players in clearing apoptotic cells during cutaneous injury. Most surprisingly, combining blockade of Slc7a11 together with apoptotic cells can significantly improve wound healing kinetics. This accelerated wound healing is seen not only in wild-type mice but more importantly in diabetes-prone db / db mice. While anti-inflammatory soluble factors are known to be released from efferocytic phagocytes, transcriptomic analysis of Slc7a11-deficient dendritic cells identified GDF15 as one important extracellular mediator that drives wound closure downstream of Slc7a11. Thus, inhibition of Slc7a11 function and addition of certain soluble downstream factors (e.g., GDF15) can improve cutaneous wound healing in diabetic conditions.
[0099] In summary, starting from unbiased transcriptomics of efferocytic dendritic cells, the present invention reveals a new approach to improve cutaneous wound healing by identifying Slc7a11 as a brake on dendritic cell phagocytosis and mechanistic studies, a strategy that is relevant for chronic wound healing management, such as diabetic wound healing.
[0100] method Murine tissue processing. Cells from ears of Slc7a11 KO and control littermates were isolated as previously described. 60Briefly, ear skin samples were collected by cutting at the base of the ear and incubated overnight at 4°C with 200 μg / mL Dispase II (Bacillus polymerase grade 2; from Roche, Basel, Switzerland) to facilitate manual cutting and isolation of cells. Small pieces of skin were further digested with 1.5 mg / mL collagenase type 4 (Worthington, Lakewood, NJ) and 10 U DNase (Roche) in RPMI medium buffered with HEPES and supplemented with 2% fetal bovine serum. The suspension was resuspended every 30 min and fresh digestion buffer was provided for a total of 90 min at 37°C. After digestion, the cell suspension was filtered to remove debris and blood clots. For spleen single cell suspensions, spleens were digested for 30 min in RPMI medium supplemented with 0.01 U / mL DNase I (Roche) and 0.02 mg / mL Liberase (Roche). Red blood cells were removed with a 1x solution of RBC lysis buffer (Biolegend; #420301). For bone marrow progenitor cells, bone marrow was isolated from femurs and tibias of 8- to 12-week-old mice.
[0101] Cell isolation. Single cell suspensions of digested ears and spleens were further enriched for phagocytes by depleting lymphocyte populations. Depletion was performed with monoclonal biotin-linked antibodies against CD3e (145-2C11, #13-0031-82 eBioscience™), CD19 (eBio1D3-1D3, #13-0193-82 eBioscience™), NK1.1 (PK136, #13-5941-82 eBioscience™), followed by collection of non-depleted cells using MagniSort™ streptavidin negative selection beads (#MSNB-6002-74 ThermoFisher). Bone marrow-derived dendritic cells and macrophages were isolated by culturing bone marrow progenitors in GM-CSF-supplemented medium for 10 days and M-CSF-supplemented medium for 6 days, respectively, and by culturing bone marrow progenitors in GM-CSF-supplemented medium for 10 days and M-CSF-supplemented medium for 6 days, respectively, as previously described. 61 , produced from mice.
[0102] Flow cytometry and cell sorting. Immunophenotyping of mouse skin or spleen was performed on single cell suspensions. Cells were stained with the following anti-mouse monoclonal fluorochrome-linked antibodies: CD24-AF488 or -eFluor450 (M1 / 69; #101816 or #48-0242-82), CD11b-BV605 (M1 / 70; #563015), CD26-FITC or -BV650 (H194-112; #559652 or #740474), CD11c-BV711 (HL3; #563048), F4 / 80-BV785 (BM8; #123141), CD45-AF700 (30-F11; #56-0451-82), MHCII (IA / IE)-eFluor780 (M5 / 114.15.2; #47-5321-82), CD172a (SIRP alpha)-PerCP-eFluor710 (P84; #46-1721-82), CD103-BUV395 (M290; #740238), CD64-BV421 or -PE / Cy7 (X54-5 / 7.1; #139309 or #139314), XCR1-BV650 (ZET; #148220), and Fc receptor blocking antibody CD16 / CD32 (clone 2.4G2, #553142). Viable cells were identified using Fixable Viability Dye eFluor 506 (#65-0866-18). Prior to measurements, counting beads (#01-1234-42) were added to the cells for some experiments. Measurements were performed on a BD LSR Fortessa cytometer and analyzed using FlowJo10 software (TreeStar). Cell sorting was performed on a FACS ARIA II and III (BD Biosciences).
[0103] Characterization of ferroptosis. To evaluate ferroptosis, we used the ferroptosis assay as previously described. 62We utilized BODIPY™ 581 / 591 (C11-BODIPY) and dihydrorhodamine 123 (DHR123) probes, which change fluorescent properties upon oxidation. Briefly, dendritic cells were treated with 5 μM erastin (#S7242, Bio-Connect BV) or 1 μM ML-162 (#AOB1514) or DMSO control before adding the fluorescent probes: 0.5 μM C11-BODIPY (#D3861, ThermoFisher) or 1 μM DHR-123 (#85100, Chemical, MI, USA) and 0.5 μM DRAQ7 cell death stain (#DR70250, BioStatus, Shepshed, UK) 1 hour before measurement.
[0104] Determination of glycogen concentration. Glycogen concentration was measured using the Glycogen Colorimetric / Fluorometric Assay Kit (#GENT-K646-10, BioVision) according to the manufacturer's instructions.
[0105] Determination of glutathione levels. Glutathione was quantified in dendritic cells 2 hours after elastin treatment using the GSH / GSSG-Glo Assay luminescence-based system according to the manufacturer's instructions (#V6611, Promega). The GSH / GSSG ratio is calculated after luminescence measurement (relative light units, RLU) and interpolation of glutathione concentrations from a standard curve. Both glycogen and glutathione data are reported as fold changes from DMSO (vehicle)-treated or WT cells.
[0106] Seahorse analysis. 100000 BMDCs were seeded in Seahorse 96-well tissue culture plates (Agilent Technologies). Plates were left for 30 min to allow cells to settle, then placed in an incubator overnight. Adherent cells were treated with 5 μM erastin (#S7242, Bio-Connect BV) or 200 μM CP-91149 (#S2717, Bio-Connect BV). 2 h prior to Seahorse analysis. Cells were switched to serum-free Seahorse medium prior to the assay according to the manufacturer's instructions. For basal ECAR and OCR, cells were subjected to the XF Real-time ATP Rate Kit (#103592-100, Agilent Technologies). For respiratory capacity assessment, cells were subjected to the XF Cell Mito Stress Test Kit (#103015-100, Agilent Technologies). Sequential injections of oligomycin, FCCP, and rotenone / antimycin A were performed at 1.5 μM, 1.0 μM, and 0.5 μM, respectively.
[0107] Efferocytosis assay. For induction of apoptosis, human Jurkat T cells were stained with CypHer5E (#PA15401, GE Healthcare), or TAMRA (#C-1171, Invitrogen), or pHrodo™ Green STP Ester (#P35369, ThermoFisher), resuspended in RPMI with 5% fetal bovine serum, treated with 150 mJ / cm2 UV-C irradiation (Stratalinker), and incubated for 4 hours at 37°C with 5% CO2. Dendritic cells were incubated with apoptotic targets at a phagocyte:target ratio of 1:5 for the indicated times. Phagocytosis was measured using a flow cytometry-based assay. 21or Incucyte Live-cell imaging. As alternative targets for phagocytosis, dendritic cells were incubated with pHrodo™ Green E. coli BioParticles™ (#P35366, ThermoFisher) or Streptavidin Fluoresbrite® YG Microspheres, 2.0 μm (briefly, beads) at a phagocyte:target ratio of 1:5 for the indicated times. Where applicable, cells were pretreated for 1 hour with 5 μM erastin (#S7242, Bio-Connect BV), 200 μM CP-91149 (#S2717, Bio-Connect BV), 0.2 mM 2-DG (2-deoxy-D-glucose; #D8375-1G, Sigma), 5 μM UK5099 (#PZ0160, Sigma), 40 μM DON (6-diazo-5-oxo-L-norleucine; #D2141-5MG, Sigma), 10 μM 3-BP (3-bromo-2-oxopropionic acid, #376817-M, Sigma), 10 mM glutamate (#6106-04-3, Sigma) prior to addition of targets.
[0108] siRNA experiments. Dendritic cells were treated with Dharmacon SMARTpool: Accell Slc7a11 siRNA (#E-047420-00-0010), Accell Slc7a1 siRNA (#E-042922-00-0005), Accell Slc7a5 siRNA (#E-041166-00-0010) or Accell Non-targeting siRNA#1 (#D-001910-01-05), and Accell Non-targeting siRNA#4 (#D-001910-04-05) according to the manufacturer's instructions 2 days before the phagocytosis assay.
[0109] qRT-PCR. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) and cDNA was synthesized using the Sensifast cDNA Synthesis Kit (#BIO-650504) according to the manufacturer's instructions. Quantitative gene expression analysis of mouse genes was performed using mouse sequence-specific Taqman probes (Applied Biosystems) that are non-cross-reactive with human sequences, run on a Roche Lightcycler 480-384.
[0110] ELISA. GDF15 levels were measured in the supernatants of dendritic cells or whole skin lysates by using the Mouse / Rat GDF-15 Quantikine ELISA Kit (#MGD150, R&D Systems). For skin lysates, whole (shaved skin) was lysed in 50 mM Tris-HCl (pH 8.5) using a Precellys 24 tissue homogenizer, and 25 μg of lysate per sample was used for ELISA.
[0111] RNA sequencing. Wild-type or Slc7a11-deficient BMDCs were co-cultured with apoptotic Jurkat cells for 4 hours, unbound Jurkat cells were removed by washing with PBS, and phagocytic BMDCs were isolated by sorting on a BD FACSAria™ III Cell Sorter. Total RNA was extracted and mRNA libraries were prepared using the Illumina Novoseq6000 platform from Novogene. HISAT2 was selected to map the filtered sequencing reads to the reference genome. The BAM files containing the mapping results were counted using the feature count function of the R package Rsubread. Although counting was performed using both mouse and human genomes for comparison, downstream analysis was performed only on the mouse data. DEG analysis was then performed using DESeq2 considering all genes with FDR ≤ 0.05 and 0.58 ≤ Log2FC ≤ -0.58. All genes obtained from the analysis were curated using multiple methods including literature search, and function determination (known or predicted) by UniProt.
[0112] scRNA sequencing and analysis. Control wild type (WT: Cre-negative OTULIN fl / fl ; n = 1) skin, as well as lesional (L; n = 3) and non-lesional (NL; n = 2) Δ Ker The single-cell RNA sequencing (scRNAseq) dataset on live cells sorted from OTULIN skin is fully described in Hoste et al., (Nature Communications, 2021, In Press).
[0113] Bioinformatics analysis. Gene sets were tested for unidirectional enrichment and visualized using the Triwise package. Gene expression datasets based on average normalized gene counts for each of the three dendritic cell (DC) populations (lung, skin, and spleen) analyzed in RStudio Version 1.2.1335 and extracted from the ImmGen Microarray V1 dataset "GSE15907".
[0114] Mice. The following mouse strains were used: C57BL / 6J, Slc7a11 KO 63 and littermates wild-type, B6.BKS(D)-Leprdb / J(db / db), and PDGFRα-H2B-eGFP reporter mice. 65 For GDF15 KO mice, ES cells (reference number 64 (as well as ) were obtained from EUCOMM and freshly produced in our transgenic mouse core facility. Mice were housed in individually ventilated cages at the VIB Inflammation Research Center in a specific pathogen-free animal facility. All experiments on mice were performed in accordance with institutional, national, and European animal regulations. Animal protocols were approved by the Ethics Committee of Ghent University.
[0115] Skin wounds and elastin regimen. Full thickness wounds were treated as previously described. 65、66 Briefly, wounds were created on the shaved dorsal skin by using an 8 mm punch biopsy needle (Stiefel Instruments) under analgesia and general anesthesia in 8-week-old female C57BL / 6J, B6.BKS(D)-Leprdb / J(db / db), GDF15KO, Slc7a11KO, and control littermates. For wound healing experiments, assuming a standard deviation of 10-15%, experimental groups of n=10 are required to obtain 90% statistical power (significance level 0.05) to detect a mean difference of 20% using a two-tailed paired T-test. No animals were excluded from the experiment.
[0116] For topical application, mice were inoculated with imidazole ketone elastin (20 mg kg in 100 μL PBS) at the wound site and for two consecutive days. -1 IKE; MedChemExpress, #HY-114481) or recombinant human GDF-15 (0.7 mg kg in 100 μL PBS -1 ; R&D Systems, #9279-GD-050) or RSL3 (20 mg kg in 100 μL PBS -1 Mice were injected intradermally with either Elastin Regimen (Elastin Regimen; Sellechem, #S8155) or the respective vehicle control (DMSO or 4 mM HCl in 100 μL of PBS). In the experiments designated as "Elastin Regimen" or vehicle regimen, 5 million apoptotic Jurkat cells were administered once on day 0 in 50 μL of PBS on the dorsal skin immediately after full thickness excision biopsy. For mice injected intradermally with supernatant from efferocytic dendritic cells, supernatant from dendritic cells cultured for 16 hours with apoptotic Jurkat cells was collected, centrifuged to remove debris, and frozen or lyophilized for storage.
[0117] Histology and immunohistochemistry. Skin biopsies were fixed overnight with 4% paraformaldehyde. After a dehydration step, the samples were embedded in paraffin and sectioned at a thickness of 10 μm. Dewaxed paraffin skin sections were stained with hematoxylin and eosin stain or subjected to heat-mediated antigen retrieval (citrate buffer; pH=6), and apoptotic cells were evaluated with cleaved caspase-3 antibody (1:100; Cell Signaling Technology #9664). After the slides were incubated with secondary antibodies, peroxidase activity was detected with a diaminobenzidine (DAB) substrate kit (Cell signaling, #8059P). Nuclei were counterstained with hematoxylin stain. Cleaved caspase-3 + Positive cells were counted manually using Zen software by Zeiss. Cleaved caspase-3 + Quantification of cells was performed by an independent investigator blinded to genotype or treatment.
[0118] Immunofluorescence. Dewaxed paraffin skin sections were subjected to heat-mediated antigen retrieval (citrate buffer; pH = 6), blocked with 0.5% fish skin gelatin, 4% BSA in PBS, and immunoblotted with biotin anti-CD11c Ab (1:200, BD Pharmingen #553800), and anti-Slc7a11 Ab (1:200, in-house developed). 67 ) or cleaved caspase-3 antibody (1:100; Cell Signaling Technology #9664). As secondary antibodies, streptavidin 594 AlexaFluor (1:2000) and donkey anti-rabbit DyLight 488 (1:2000) were used in combination with DAPI.
[0119] Statistical analysis. Statistical significance was determined using unpaired two-tailed Student's t-test, one-way analysis of variance, or two-way analysis of variance using GraphPad Prism 9. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 were considered significant.
[0120] References [Table 1]
[0121] [Table 2]
[0122] [Table 3]
[0123] [Table 4]
[0124] [Table 5]
[0125]
Table 6
Claims
1. Combination of inhibitors of Slc7a11 with apoptotic cells.
2. A combination of an inhibitor of Slc7a11 and an apoptotic cell for use as a medicament.
3. A combination of an inhibitor of Slc7a11 and apoptotic cells for use in treating wound healing in a mammal.
4. An inhibitor of Slc7a11 for use in treating chronic wound healing in a mammal.
5. The inhibitor for use according to claim 4, wherein the inhibitor is selected from a small compound, an antibody, a gapmer, an shRNA, a synthetic siRNA, an antisense oligonucleotide selected from locked nucleic acid (LNA), peptide nucleic acid (PNA), or morpholino, CRISPR, TALEN, or zinc finger nuclease targeting Slc7a11.
6. 6. The inhibitor for use according to claim 4 or claim 5, wherein the chronic wound healing is diabetic wound healing, arterial or venous wound healing, or pressure wound.
7. A composition comprising an inhibitor of Slc7a11 as defined in claim 5 and GDF-15.
8. 8. The composition of claim 7 for use as a medicament.
9. 8. The composition of claim 7 for use in treating chronic wound healing in a mammal.
10. 6. A pharmaceutical composition comprising an inhibitor as defined in claim 4 or claim 5 for use for treating a chronic wound in a mammal.
11. 11. The pharmaceutical composition of claim 10, wherein the chronic wound healing is diabetic wound healing, arterial or venous wound healing, or pressure wound.
12. A pharmaceutical composition comprising a combination as defined in claim 1.
13. 13. The pharmaceutical composition of claim 12 for use in treating wound healing.
